Zydus Lifesciences Limited has reported strong financial performance for the fourth quarter and full year ended March 31, 2026, driven by revenue growth, improved profitability, and sustained investments in research and development.

The company’s Board of Directors, at its meeting held on May 19, 2026, approved a 100 percent dividend for FY26 and also cleared a share buyback proposal worth up to Rs. 11,000 million at a price of Rs. 1,150 per equity share, representing a 16 percent premium over the closing price on May 18, 2026.

For Q4 FY26, revenue from operations stood at Rs. 75,870 million, reflecting a 16 percent year-on-year increase. EBITDA for the quarter rose 20 percent year-on-year to Rs. 25,544 million, while EBITDA margin improved by 110 basis points to 33.7 percent.

Adjusted net profit for the quarter increased 15 percent year-on-year to Rs. 15,929 million. The company invested Rs. 6,982 million in research and development during the quarter, accounting for 9.2 percent of revenues, while organic capital expenditure stood at Rs. 3,577 million.

For the full financial year FY26, revenue from operations increased 17 percent year-on-year to Rs. 271,484 million. EBITDA grew 20 percent to Rs. 84,751 million, with EBITDA margin improving by 80 basis points to 31.2 percent.

Adjusted net profit for FY26 stood at Rs. 54,564 million, registering a 15 percent increase over the previous year. Annual R&D investments were Rs. 22,732 million, representing 8.4 percent of revenues, while organic capital expenditure for the year stood at Rs. 17,145 million.

The company also maintained a strong financial position, with a net debt-to-equity ratio of 0.16x and net debt-to-EBITDA ratio of 0.50x as of March 31, 2026.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, said, “We closed FY26 on a strong note, delivering on our commitments — both on revenue growth and profitability. We are confident our pipeline will drive overall growth visibility while future growth engines begin to deliver. Our near-term priorities are clear: maintain consistent quality standards, integrate our recent acquisitions, and capture synergies swiftly. Finally, our strong balance sheet ensures we have the flexibility to invest and strengthen our businesses further.”